Comparing Outcomes Pre- and Post-Cancer Drugs Fund: What Can We Learn?
Now that a number of medicines have exited the Cancer Drugs Fund (CDF), the ABPI commissioned Lumanity to explore how it has been operating, including how well clinical outcomes are being predicted by manufacturers at the time of entry to the fund on initial appraisal. The findings are published in this report ‘Comparing Outcomes Pre- and Post-Cancer Drugs Fund: What Can We Learn?’
Last modified: 20 September 2023
Last reviewed: 20 September 2023